Search alternatives:
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
2012 mean » 21 mean (Expand Search)
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
2012 mean » 21 mean (Expand Search)
-
1801
-
1802
-
1803
-
1804
HoxA9 represses and C/EBPα activates the <i>Cebpa</i> +8 kb enhancer in immature myeloid cells.
Published 2019Subjects: -
1805
-
1806
-
1807
-
1808
DataSheet_2_Decreased expression of SCARA5 predicts a poor prognosis in melanoma using bioinformatics analysis.xlsx
Published 2023“…Background<p>It has been established that the scavenger receptor class A member 5 (SCARA5) functions as a tumor suppressor gene in various cancer types. …”
-
1809
DataSheet_3_Decreased expression of SCARA5 predicts a poor prognosis in melanoma using bioinformatics analysis.xlsx
Published 2023“…Background<p>It has been established that the scavenger receptor class A member 5 (SCARA5) functions as a tumor suppressor gene in various cancer types. …”
-
1810
Table_1_FMT intervention decreases urine 5-HIAA levels: a randomized double-blind controlled study.DOCX
Published 2024“…However, in the placebo group, GSRS, CARS, and SRS scores showed no significant changes, while ABC scores decreased from 72 to 58.75 (p = 0.034). The FMT group also showed a significant reduction in urinary 5-hydroxyindoleacetic acid (5-HIAA) levels from 8.6 to 7.32 mg/L (p = 0.022), while other metabolites showed no significant changes.…”
-
1811
-
1812
-
1813
DataSheet_1_Decreased expression of SCARA5 predicts a poor prognosis in melanoma using bioinformatics analysis.xlsx
Published 2023“…Background<p>It has been established that the scavenger receptor class A member 5 (SCARA5) functions as a tumor suppressor gene in various cancer types. …”
-
1814
-
1815
-
1816
-
1817
-
1818
-
1819
-
1820